Mold-Tek Packaging Ltd

- There is no explicit mention of any current or planned fundraising through debt or equity in the transcript. - The company is focusing on progressive capacity expansion with capital expenditure (capex) of INR 50-60 crores planned for FY '24-'25. - Capex is mainly for completing the Mahad plant and adding balancing equipment at Panipat and Cheyyar plants. - The management is cautious about further capex depending on Pharma segment growth, which might require additional capacity expansion mid-year if the business develops well. - No direct references were made to raising funds via new loans or equity issuance; existing financial costs have increased due to recent investments. - Overall, fundraising plans, if any, were not disclosed or discussed in this transcript.

- Capex of INR 50-60 crores planned for FY '24-'25, including building the Mahad plant (~INR 20 crores) and balancing equipment/ construction at Panipat and Cheyyar (~INR 15-20 crores). - Progressive capacity expansion from current 47,000 tons to ~60,000 tons by end of FY '25. - Pharma capacity enhancement under consideration, potentially starting mid-FY '24-'25 if market response remains positive. - Continuous capex expected over 1-1.5 years focusing on Pharma and other segments. - New facilities: Panipat plant inauguration planned by February end; Cheyyar plant started January. - Pharma product lines (effervescent tubes, canisters, HDPE bottles, CRC caps) targeted for commercial production by end of calendar year 2024, peak production by Q1 FY '25. - Focus on capacity utilization and new product launches at Panipat to drive Food & FMCG growth. - Exports for effervescent tubes and canisters expected to start next financial year.

- Volume growth target for FY '24-'25 is at least 15-20%, with potential for up to 20% in thin wall Food & FMCG segment. - Capacity expected to increase from current 47,000 tons to about 57,000-60,000 tons by end of next financial year. - Pharma packaging capacity expansion may start mid-FY '24-'25, potentially driving significant future growth. - Square Packs (Qpacks) have shown over 100% volume growth, expected to grow 30-40% next year. - Paint segment volume growth expected to return to double digits with new plants and clients like ABG and Asian Paints. - EBITDA margin aimed to cross 20% within 1-2 years, driven by Pharma and other segments. - Revenue growth impacted by raw material prices but volume growth expected to translate into higher sales.

- EBITDA margin is close to 18.9%, expected to cross 20% during FY '24-'25 if Pharma segment progresses well; else, may take 1 more year. (Page 14) - EBITDA per kg targeted to improve back to INR 40 in FY '24-'25 and likely improve further with Pharma success. (Pages 14, 12) - Revenue growth depends on raw material prices; volume growth targeted at 15-20% for next financial year. (Page 14) - Pharma segment expected to contribute 5-8% to top line from year 2 onwards, progressively improving EBITDA per kg. (Pages 12, 14) - Food and FMCG segment set to grow by 20% in next financial year, driven by Panipat plant ramp-up and new products. (Pages 9, 12, 14) - Paint segment shipment volumes expected to increase with new plant (Satara) coming online, aiming for double-digit growth next year. (Page 14) - Continuous capex of INR 50-60 crores planned for FY '24, '25 supporting capacity ramp-up to 57,000-60,000 tons by end FY '25. (Pages 17-18)

- Mold-Tek Packaging operates mostly on a rolling order basis with major clients, who give monthly orders based on demand. - There is no fixed or large pending order book as such; smaller clients place orders periodically based on their needs. - Major clients like Asian Paints and others have open orders with monthly price revisions linked to raw material fluctuations. - The company maintains an open order system rather than a backlog of pending orders. - This approach allows flexibility in managing production according to client requirements without accumulating a large pending order book.